NCT03871036View on ClinicalTrials.gov

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

September 7, 2023

Study Completion Date

January 15, 2025

Conditions
Urothelial Carcinoma
Interventions
DRUG

Tremelimumab

See experimental arm description for more details.

DRUG

Durvalumab

See experimental arm description for more details.

DRUG

Paclitaxel

See experimental arm description for more details.

Trial Locations (1)

Unknown

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03871036 - Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | Biotech Hunter | Biotech Hunter